The Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) Protocol
Arthritis, Rheumatoid
About this trial
This is an interventional treatment trial for Arthritis, Rheumatoid focused on measuring Rheumatoid Arthritis, Infliximab infusions, Methotrexate, Remicade
Eligibility Criteria
Inclusion Criteria: Previous diagnosis of RA according to the revised 1987 criteria of the American Rheumatism Association (Arnett et al., 1988) patients must have a minimum of 8 tender and 4 swollen joints with disease diagnosed at least 3 months prior to screening patients must have been using oral or parenteral MTX for at least the previous 3 months, and at a stable dose of 7.5 to 25 mg per week for at least the previous 1 month women of childbearing potential must test negative for pregnancy and be using adequate birth control measures patients must have a documented purified protein derivative (PPD) skin test performed at prescreening. Exclusion Criteria: Patients who have received any prior treatment with infliximab or with any other therapeutic agent targeted at reducing tumor necrosis factor (TNF) (e.g., etanercept, pentoxifylline or thalidomide) within the previous 3 months patients who are incapacitated history of infected joint prosthesis within the previous 5 years patients with a concomitant diagnosis of congestive heart failure (CHF), history of or known malignancy within the previous 5 years, cases of active or latent tuberculosis (TB), acute or chronic serious infections within the past 3 months known substance abuse (drug or alcohol) within the previous 3 years